Ryman stock falls after Melbourne consent delays
Record year for Ryman but shareholders sell down. With special audio feature.
Hot Topic
Summer features
Ryman Healthcare [NZX: RYM] maintains it will reach this year’s growth targets, despite consent delays in Melbourne.
The consistently strong performer produced its highest yet annual result this morning, with underlying profit – which removes fair value changes from its property portfolio – rising
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Calida Smylie
Fri, 20 May 2016
Fri, 20 May 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Ryman stock falls after Melbourne consent delays
58354